



# Harnessing The Power of Sulforaphane

July 2022





THIS PRESENTATION (AS DEFINED BELOW) IS CONFIDENTIAL AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES (INCLUDING ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA), CANADA, AUSTRALIA, JAPAN, NEW ZEALAND AND THE REPUBLIC OF SOUTH AFRICA OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL.

This document and the related verbal presentation (together the "Presentation") are for your information only, and are being delivered by Evgen Pharma plc (the "Company" or "Evgen") which trades on the AIM market of the London Stock Exchange under ticker EVG.

By attending this Presentation, you agree to be bound by the following conditions. Please note that the information in this Presentation has yet to be announced or otherwise made public and some or all of the information in this Presentation or any discussion surrounding the Presentation may constitute inside information relating to the securities of the Company within the meaning of the insider dealing provisions of the Criminal Justice Act 1993 and/or of the EU Market Abuse Regulation (Regulation 596/2014) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). By accepting this Presentation the recipient agrees to comply with its obligations under the MAR, including by not making use of any of inside information for the purpose of dealing, or of counselling or procuring any other person to deal, in the securities of the Company. The information and opinions contained in this Presentation have not been independently verified, are provided as at the date hereof and are subject to amendment, revision and completion without notice. No person is under any obligation to update or keep current the information contained in this Presentation. No representation, warranty or undertaking, express or implied, is made by the Company, its advisers or representatives, or their respective officers, employees or agents as to, and no reliance should be placed on, the fairness, accuracy, completeness, correctness or reasonableness of the information or the opinions contained herein. The Company, its advisers or representatives, or their respective officers, employees and agents expressly disclaim any and all liability which may be based on this and any errors therein or omissions therefrom.

This document is not an admission document or a prospectus. This document does not constitute or form any part of any offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for, any shares in the Company, nor shall it or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any contract therefor. This Presentation has not been authorised or approved for the purposes of section 21 of the Financial Services and Markets Act 2000 and therefore it is being delivered for information purposes within (a) the United Kingdom only to persons (i) who have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or are high net worth entities falling within Article 49(2)(a) to (d) of the Order and investment personnel of any of the foregoing (each within the meaning of the Order); and (ii) who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation (Regulation (EU) 2017/1129) as it applies in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 ("Qualified Investors"); and (iii) to whom the Presentation may otherwise lawfully be communicated; (b) the European Economic Area (the "EEA") only to Qualified Investors (all such persons together being referred to as "Relevant Persons" and each a "Relevant Person"). By accepting this Presentation and not immediately returning it, the recipient represents and warrants that they are a Relevant Person and agrees to be bound by the following conditions. This Presentation is not to be disclosed to any other person or used for any other purpose.

If you are in any doubt about the contents of this document, you should consult a person authorised under the Financial Services and Markets Act 2000 who specialises in advising on the acquisition of shares and securities of unlisted companies. You should be aware that an investment in the Company involves a high degree of risk and investors should be aware of such risks and should rely on their own examination of the Company and make the decision to invest only after careful consideration and, if appropriate, consultation with an independent financial adviser. Any investment or investment activity to which this document relates is only available to Relevant Persons. Persons of any other description should not rely on this document or act on its contents for any purpose whatsoever and should return it to the Company immediately.

The distribution of this Presentation in certain jurisdictions may be restricted by law, and persons into whose possession this Presentation comes should inform themselves about, and observe, any such restrictions. Although reasonable care has been taken to ensure that the facts stated in this Presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this Presentation have not been verified by the Company or any other person. Accordingly no representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this Presentation and no reliance should be placed on such information or opinions. None of the Company, or any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this Presentation. No part of this Presentation, or the fact of its distribution, should form the basis of or be relied upon in connection with any contract or commitment or investment decision whatsoever.

Recipients of this Presentation are not to construe its contents, or any prior or subsequent communications from or with the Company or its representatives as investment, legal or tax advice. In addition, this Presentation does not purport to be all-inclusive or to contain all of the information that may be required to make a full analysis of the Company or any transaction to be entered into by any member of the Evgen group. No undertaking, representation or warranty, express or implied, is given by the Company, any member of the Evgen group, or any of their respective current or proposed directors, officers, partners, employees, secondees, agents or advisers or any other person as to the accuracy or completeness of the information or as to the opinions contained in this document and no liability is accepted for any such information or opinions. Further, the information in this Presentation is not complete and may be changed. Recipients of this Presentation should each make their own independent evaluation of the information and of the relevance and adequacy of the information in this document and should make such other investigations as they deem necessary.

This Presentation may contain forward-looking statements that reflect the Company's current views and expectations regarding future events. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "envisages", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "could", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward looking statements. These forward-looking statements include matters that are not historical facts and speak only as of the date of this Presentation. They appear in a number of places throughout this document and include statements regarding the Company and the directors, and the directors' current intentions, beliefs or expectations concerning, amongst other things, to management's strategic vision, aims and objectives, the conduct of clinical trials, the filing dates for product licence applications and the anticipated launch of specified products in various markets, the Company's ability to find partners for the development and commercialisation of its products as well as the terms for such partnerships, anticipated levels of demand for existing products and products in development, the effect of competition, anticipated efficiencies, trends in results of operations, margins, the overall pharmaceutical market and exchange rates, are all forward looking in nature.

# Evgen - A Clinical Stage Drug Development Company


Focus on breast cancer, glioma and other cancers

SFX-01 has three molecular targets, STAT 3, Nrf2 and SHP2


- Developing a new class of pharmaceuticals - based on highly biologically active “sulforaphane” - applications in multiple therapeutic areas based on a network of targets
- Strong third party pre-clinical and clinical data on sulforaphane
- Four target diseases in cancer and inflammation, each with high unmet clinical needs
- Unique platform technology – Sulforadex<sup>®</sup>, stabilises unstable sulforaphane, lead SFX-01
- Strong, granted IP covering composition, manufacturing and novel derivatives
- Highly experienced board and management
- Business model: establish proof of concept and partner. Multiple value inflection points
- £9.0m in cash as at 31 March 2022

# Strategy and Business Model

## Establish proof of concept and partner

- Exploit leading, patented technology in sulforaphane science
  - Developing our lead molecule, SFX-01, in selected cancers and inflammatory disease to deliver phase II proof of concept data, and then out-license
  - Early partnering of non-core indications with suitable licensees
  - Support academic and commercial partners with compelling scientific rationale in cancer and other diseases and markets beyond our development programmes
  - Broaden pipeline through acquisition/licensing of sulforaphane analogues and other complementary molecules
- 

# Pipeline



# Recent Achievements

<b>Academic Collaborations</b>	<p><b>June 2022.</b> New collaboration with University of Michigan on bowel cancer.</p> <p><b>May 2022.</b> New academic collaboration with University “La Sapienza” Rome, further evaluating potential radiosensitisation by SFX-01 <i>in vitro</i>.</p>
<b>Manufacturing,</b>	<b>2021 - 2022.</b> Scale-up of the active ingredient in SFX-01 to commercial scale achieved with a number of process improvements
<b>New EC Tabs</b>	New formulation of SFX-01 generated in enteric coated tablet form enabling scale-up to supply late-stage clinical trials and commercial use.
<b>mBC</b>	<p><b>March 2022.</b> Expansion of pre-clinical collaboration with the University of Manchester, Manchester Breast Biology Centre and The Christie Hospital. Generate data to optimise positioning of SFX-01 in breast cancer treatment following promising Phase 2a clinical data.</p> <p><b>Out license market average \$19m up front, \$144m total, 10-14% royalty*</b></p>
<b>FDA</b>	<p><b>January 2022.</b> Pre-IND meeting feedback.</p> <p><b>September 2021.</b> Orphan Drug designation achieved with FDA for malignant glioma.</p>
<b>MHRA</b>	<b>January 2022.</b> UK Scientific Advice received.
<b>Glioma</b>	<b>October 2021.</b> Publication of powerful pre-clinical data including significant survival benefit, <b>Out licence market average \$11m up front, \$90m total, 8-12% royalty*</b>
<b>Onc 3</b>	Collaboration with The Weatherall Institute, University of Oxford demonstrate <i>in vitro</i> efficacy in rare pediatric disease JMML and more common adult blood cancer AML.
<b>Partner</b>	Sulforadex technology licence concluded with Juvenescence for non-pharmaceutical applications using naturally derived sulforaphane. <b>\$10.5m in milestones / options plus royalty. Market launch late 2023</b>



\* Source Global Data, Pre-clinical to Phase2 only, disclosed deals

# Outlook

<b>Phase 1 PK/PD Study</b>  Q4 2022	Healthy volunteer trial start Q4 2022 with new SFX-01 formulation; EC tablet suitable for commercial use. Pharmacodynamic parameters measured to assess target engagement.
<b>GBM patient study, Phase 1b/2a</b>  Q4 2022	Final preclinical work in GBM being completed and now in late-stage preparation for a Phase Ib/IIa trial due to start in Q4 2022.  UK/Europe, multi centre, multi country, adaptive design.
<b>2023 Newsflow</b>	Results of pre-clinical collaborations x4  Results of volunteer study PK/PD  Top line Results of GBM patient study  Juvenescence Launch – low seven figure milestone



# SFX-01 GBM Programme, Design to PoP

PK pharmacokinetics  
 PDc pharmacodynamic  
 PoP proof of principle  
 TME tumour microenvironment  
 TMZ temozolomide  
 ND newly diagnosed

## In Vivo GBM TME Model Studies (SFN + radiotherapy)

- Enteric Tablet CMC Program
- PK Assay Refinement Program:
  - SFN
  - Metabolites
- PDc Assay Program:
  - Validated assays
  - PK:PDc assessment

**Module 1 Patient Study 'Phase 0'**  
 Recurrent Gliomas  
 Monotherapy: Tolerability/PDc  
 Add in TMZ

Safety  
 Tolerability  
 PDc biomarkers  
 PK

**Delivers:**

- Tumour PK
- PDc PoM and PoP
- Tolerability
- Dose to initiate ND GBM Modules

**HV Study**  
 Monotherapy MAD: PK/PDc  
 Randomised double blind  
 SFX-01 vs placebo

PK  
 PDc biomarkers  
 Safety  
 Tolerability

**Delivers:**

- PK:PDc
- Tolerability

**Supports:**

- Non-malignant disease strategy
- Oncology strategy



# Financials

<b>P&amp;L</b>	Operating loss of £3.2m (2021: loss of £3.2m) Post-tax loss of £2.7m (2021: loss of £2.7m)
<b>Cash flow</b>	Cash outflow from operations of £2.6m (2021: outflow of £2.9m).
<b>Y/E cash position</b>	Cash and short-term deposits at 31 March 2022 of £9.0m (31 March 2021: £11.6m).
<b>Cash Runway</b>	To Q4 2023

# Management and Board



**Dr Huw Jones**  
CEO

Over 30 years' experience of leadership in public and private R&D-based companies within the biotechnology and pharmaceutical sector: Chronos Therapeutics, CV Therapeutics, Elan Corp and SB (GSK)



**Richard Moulson**  
CFO

Qualified chartered accountant with over 20 years experience working as a CFO for UK quoted and venture capital-owned companies including: Intercytex Group Plc, ReNeuron Group plc and Cobra Therapeutics Ltd



**Barry Clare**  
Chairman

Former main Board member of Boots Company plc and Chairman UHSM Foundation Trust



**Dr Sue Foden**  
NED

NED and Chair of the Remuneration Committee at BTG and Vectura Plc. Has previously Chaired Bergenbio



**Dr Alan Barge**  
NED

Former CMO of ASLAN Pharmaceuticals and former VP and Head of Oncology and infection at AZ



**Susan Clement-Davies**  
NED

Over 25 years of capital markets and investment banking experience and former Managing Director of Citigroup and Salomon Smith Barney and recently Torreyya



**Dr Helen Kuhlman**  
CBO

Over 20 years' experience in government funding and equity investment together with scientific and business roles in public and private R&D-based biotechnology companies



**Dr Glen Clack**  
CMO

Over 25 years' experience in oncology drug development with a specialism in translational medicine

# Medical and Scientific Advisors



**Dr Mary Stuart**

Senior oncology physician.  
Previously Global Clinical  
Leader/medical Science Director at  
AZ and CSL at Roche



**Dr Sacha Howell**

Consultant Medical Oncologist at  
Christie Foundation Trust  
Clinical Senior Lecturer at Division of  
Cancer Sciences, Manchester  
University



**Professor Rob Clarke**

Professor of Breast Biology, University  
of Manchester



**Professor Phillip Eaton**

Professor of Cardiovascular  
Biochemistry, Queen Mary University  
of London



**Professor Albena Dinkova-Kostova**

Professor of Chemical Biology,  
Dundee and Adjunct Professor at  
Johns Hopkins University



**Professor Anthony Chalmers**

Chair of Clinical Oncology at the  
University of Glasgow and Director of  
the CRUK RadNet Centre of Excellence  
in Radiotherapy Research.



**Professor Claudio Festuccia**

Professor of Applied Clinical Studies at  
L'Aquila University



Evgen Pharma Plc  
enquiries@evgen.com  
[www.evgen.com](http://www.evgen.com)

